Clinical Trial Detail

NCT ID NCT01353625
Title Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

chronic lymphocytic leukemia

prolymphocytic leukemia

CLL/SLL

multiple myeloma

prostate cancer

Advanced Solid Tumor

non-Hodgkin lymphoma

Ewing sarcoma of bone

Therapies

CC-115

Age Groups: adult senior

No variant requirements are available.